Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.73 |
| ▸ | BCR | P11274 | 1/20 | 0.73 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22817901 | 1.00 | ABL1 (0.74) | ABL1KCNH2BCRCRBN | |
| SCHEMBL20419089 | 0.94 | ABL1 (0.65) | ABL1KCNH2BCRCRBN | |
| SCHEMBL22817900 | 0.94 | ABL1 (0.65) | ABL1KCNH2BCRCRBN | |
| SCHEMBL20419084 | 0.90 | ABL1 (0.65) | ABL1KCNH2BCRCRBN | |
| SCHEMBL22817899 | 0.90 | ABL1 (0.65) | ABL1KCNH2BCRCRBN | |
| SCHEMBL22837850 | 0.89 | ABL1 (0.61) | ABL1KCNH2 | |
| SCHEMBL21480436 | 0.89 | ABL1 (0.60) | ABL1KCNH2BCRCRBN | |
| SCHEMBL20419080 | 0.88 | ABL1 (0.73) | ABL1 | |
| SCHEMBL28369138 | 0.87 | ABL1 (0.76) | ABL1KCNH2BCRCRBN | |
| SCHEMBL20419078 | 0.87 | ABL1 (0.76) | ABL1KCNH2BCRCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3553057-B1 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2022-10-26 | — | — | EP | disclosed |
| US-11319317-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-11319317-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20210171517-A1 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2021-06-10 | — | — | US | disclosed |
| US-20210171517-A1 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2021-06-10 | — | — | US | disclosed |
| US-10875853-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2020-12-29 | — | — | US | disclosed |
| US-10875853-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2020-12-29 | — | — | US | disclosed |
| EP-3553057-A1 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen Targetrx, Inc. (CN) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018133826-A1 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | 深圳市塔吉瑞生物医药有限公司 | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875853-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | MAP2K2, MAP2K5, MAP2K4 | ABL1 45/4885KCNH2 941/4885BCR 973/4885 |
| US-20210171517-A1 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | MAP2K2, MAP2K5, MAP2K4 | ABL1 45/4885KCNH2 941/4885BCR 973/4885 |
| US-11319317-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | MAP2K2, MAP2K5, MAP2K4 | ABL1 45/4885KCNH2 941/4885BCR 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.